Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Study to Evaluate Subcutaneously Delivered Long-Acting MASP-2 Inhibitor OMS1029

Next Previous
X
Search
Trial Profile

A Clinical Study to Evaluate Subcutaneously Delivered Long-Acting MASP-2 Inhibitor OMS1029

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OMS 1029 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Omeros Corporation

    • Most Recent Events

    • 09 Aug 2022 According to an Omeros Corporation media release, first dose administered earlier this week.
    • 10 May 2022 According to an Omeros Corporation media release, enrollment is targeted to begin this summer.
    • 01 Mar 2022 According to an Omeros Corporation media release, based on PK/PD data to date, dosing in humans is expected to be once-monthly to once-quarterly by subcutaneous or intravenous administration.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top